2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Pfizer Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #73 · 輝瑞公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | PFE |
| Company | Pfizer Inc. |
| GICS sector / industry | Health Care (XLV) / Pharmaceuticals |
| S&P 500 rank (by weight) | #73 · 0.24% (Oct 29, 2026) |
| Sector rank | #10 in Health Care (Oct 29, 2026) |
| Headquarters | New York, New York |
| Founded | 1849 |
| CEO | Albert Bourla |
| Employees | Approximately 81,000 (FY2024) |
| Market cap | $170.71B (Oct 30, 2026) |
| Share price | $30.52 (Oct 30, 2026 close) |
| SEC filings | EDGAR — CIK 0000078003 |
WHAT IT DOES
Pfizer researches, develops and sells prescription medicines and vaccines worldwide.
Its portfolio spans primary care, specialty care and oncology, with Eliquis, Prevnar and Comirnaty among the largest products.
The company reports a single Biopharma segment; the table above groups products for readability.
BUSINESS SEGMENTS
| Primary Care | Medicines for common conditions, including vaccines and antivirals. |
| Specialty Care | Medicines for rare and complex conditions. |
| Oncology | Cancer medicines and therapies. |
HISTORY
| Year | Milestone |
|---|---|
| 1849 | Charles Pfizer and Charles Erhart found Pfizer in Brooklyn, New York. |
| 1998 | Pfizer launches Viagra. |
| 2009 | Pfizer acquires Wyeth. |
| 2020 | Pfizer and BioNTech co-develop Comirnaty, the first authorized COVID-19 vaccine. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $62.58B (FY2025 revenues) |
| Operating income | Not available |
| Net income | $7.77B (FY2025 net income attributable to Pfizer Inc.) |
| Diluted EPS | $1.36 (FY2025 diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Pfizer is a scale pharmaceutical company in transition: COVID-era revenues are fading, and the investment case rests on the oncology pipeline from Seagen and new launches replacing expiring blockbusters. The risk is the patent cliff arriving faster than the pipeline.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | Pfizer Inc. Form 10-K for the year ended December 31, 2024 (revenues $62.66B; net income attributable to Pfizer Inc. $8.03B; diluted EPS $1.41). Operating income was not stated as a clean single line in the sources consulted and is shown as Not available. |
| Index weight & ranks | Slickcharts S&P 500 weights, Oct 29, 2026 close, fetched Oct 30, 2026 |
| Market cap | $170.71B (Oct 30, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
FINANCIALS
公司快照
| 股票代號 | PFE |
| 公司 | 輝瑞公司 |
| GICS 板塊/行業 | 健康護理(XLV)/製藥 |
| 標普500排名(按權重) | #73 · 0.24%(Oct 29, 2026) |
| 板塊內排名 | 健康護理 #10(Oct 29, 2026) |
| 總部 | 紐約州紐約市 |
| 成立 | 1849 年 |
| 執行長 | 艾伯樂 |
| 員工 | 約 81,000 人(2024 年) |
| 市值 | $170.71B(Oct 30, 2026) |
| 股價 | $30.52(Oct 30, 2026 收盤) |
| SEC 申報 | EDGAR — CIK 0000078003 |
業務概覽
輝瑞在全球研發、開發及銷售處方藥與疫苗。
其組合涵蓋基層醫療、專科醫療與腫瘤學,Eliquis、Prevnar 與 Comirnaty 為最大的產品。
公司按單一生物製藥分部報告;上表按產品群組整理以便閱讀。
業務板塊
| 基層醫療 | 常見疾病藥物,包括疫苗與抗病毒藥。 |
| 專科醫療 | 罕見與複雜疾病藥物。 |
| 腫瘤學 | 癌症藥物與療法。 |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1849 年 | 查爾斯·輝瑞與查爾斯·厄哈特在紐約布魯克林創立輝瑞。 |
| 1998 年 | 輝瑞推出威而鋼。 |
| 2009 年 | 輝瑞收購惠氏。 |
| 2020 年 | 輝瑞與 BioNTech 共同開發 Comirnaty——首款獲授權的新冠疫苗。 |
競爭地位
財務快照
| 總收入 | $62.58B(FY2025 收入) |
| 營業利潤 | 暫無資料 |
| 淨利潤 | $7.77B(FY2025 歸屬於輝瑞的淨利潤) |
| 稀釋 EPS | $1.36(FY2025 攤薄每股收益) |
主要風險
對標普500的重要性
輝瑞是處於轉型期的規模製藥公司:新冠時代收入正在消退,投資論點取決於 Seagen 帶來的腫瘤學管線與新品能否替代到期的大藥。風險在於專利懸崖來得比管線更快。
來源與方法
| 財務、板塊、總部 | 輝瑞截至 2024 年 12 月 31 日年度之 Form 10-K(收入 626.6 億美元;歸屬於輝瑞的淨利潤 80.3 億美元;攤薄每股收益 1.41 美元)。所查來源未以清晰單列呈現營業收入,故以「未提供」表示。 |
| 指數權重與排名 | Slickcharts S&P 500 權重,Oct 29, 2026 收盤,Oct 30, 2026 抓取 |
| 市值 | $170.71B(Oct 30, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-30 05:23 · updated 2026-11-14 23:55 · rev 8